Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of ERY974 Monotherapy in GPC3-Positive Advanced Solid Tumors
jRCT2080224729Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2019
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ERY974 in Non-hematologic malignancy, sponsored by Chugai Pharmaceutical Co., Ltd. Started Jun 2019; status: completed.
02
Drugs
ERY974
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080224729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224729.